Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Size & Outlook
Related Markets
Asia Pacific antibody drug conjugates contract manufacturing market highlights
- The Asia Pacific antibody drug conjugates contract manufacturing market generated a revenue of USD 3,631.1 million in 2024.
- The market is expected to grow at a CAGR of 12% from 2025 to 2030.
- In terms of segment, myeloma was the largest revenue generating condition in 2024.
- Lymphoma is the most lucrative condition segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2025 to 2030.
Asia Pacific data book summary
| Market revenue in 2024 | USD 3,631.1 million |
| Market revenue in 2030 | USD 7,150.3 million |
| Growth rate | 12% (CAGR from 2025 to 2030) |
| Largest segment | Myeloma |
| Fastest growing segment | Lymphoma |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Myeloma, Lymphoma, Breast Cancer |
| Key market players worldwide | Sterling Check Corp, Recipharm, Lonza Group Ltd, Catalent Inc, Sartorius AG, WuXi Biologics (Cayman) Inc, Samsung BioLogics, Piramal Healthcare, AbbVie Inc, Merck KGaA |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 40.9% of the global antibody drug conjugates contract manufacturing market in 2024.
- Globally, Asia Pacific is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 7,150.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Contract Manufacturing Market Scope
Antibody Drug Conjugates Contract Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Piramal Healthcare | View profile | 5001-10000 | Mumbai, Maharashtra, India, Asia | http://www.piramalpharmasolutions.com |
| Sterling Check Corp | View profile | 5700 | 6150 Oak Tree Boulevard, Suite 490, Independence, OH, United States, 44131 | https://www.sterlingcheck.com |
| Samsung BioLogics | View profile | 1001-5000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | https://www.samsungbiologics.com/ |
| Recipharm | View profile | 1001-5000 | Jordbro, Stockholms Lan, Sweden, Europe | http://www.recipharm.com |
| Catalent Inc | View profile | 17219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | https://www.catalent.com |
| WuXi Biologics (Cayman) Inc | View profile | 12740 | No. 108, Meiliang Road, Mashan Binhu District, Wuxi, China, People's Republic of, 214092 | https://www.wuxibiologics.com |
| Sartorius AG | View profile | 14338 | Otto-Brenner-Strasse 20, Gottingen, NI, Germany, 37079 | https://www.sartorius.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
| Merck KGaA | View profile | 62345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | https://www.emdgroup.com |
Asia Pacific antibody drug conjugates contract manufacturing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to antibody drug conjugates contract manufacturing market will help companies and investors design strategic landscapes.
Myeloma was the largest segment with a revenue share of 55.49% in 2024. Horizon Databook has segmented the Asia Pacific antibody drug conjugates contract manufacturing market based on myeloma, lymphoma, breast cancer covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific is one of the most attractive markets for contract manufacturing owing to supportive regulatory reforms, especially in countries such as India & China, and low-cost labor. Furthermore, the presence of cGMP-compliant facilities and established market players in the region is also anticipated to attract more investors & fuel the market.
In addition, the ease of conducting business in Asia Pacific is high due to relatively lower manufacturing costs, better tax benefits, and availability of skilled labor at lower costs than in developed economies, which supports the growth of contract manufacturing in Asia Pacific.
A significant number of clinical researches are conducted for ADCs in Asia Pacific, which is expected to improve the demand for ADC contract manufacturing services, and thus, boost the regional market. The region also suffers from a high prevalence of cancer, which is creating a major demand for cancer-related research, further promoting market growth.
Reasons to subscribe to Asia Pacific antibody drug conjugates contract manufacturing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific antibody drug conjugates contract manufacturing market databook
-
Our clientele includes a mix of antibody drug conjugates contract manufacturing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific antibody drug conjugates contract manufacturing market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific antibody drug conjugates contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific antibody drug conjugates contract manufacturing market size, by country, 2018-2030 (US$M)
Asia Pacific Antibody Drug Conjugates Contract Manufacturing Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
